Steris Corp is a leading provider of infection prevention and sterilization solutions for healthcare and industrial applications
The company offers a broad range of products and services designed to enhance patient safety, improve operational efficiency, and maintain compliance within hospitals and other medical environments. Steris is known for its advanced technologies in sterilization equipment, surgical instruments, and cleaning products, as well as its commitment to infection control protocols. Additionally, Steris supports healthcare facilities with training and advisory services to help optimize their sterilization processes and ensure the highest standards of hygiene.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps have persisted in the wake of COVID-19 as players destocked inventories in 2023 and 2024.
This has weighed on the returns lately as the industry has pulled back by 1.7% over the past six months. This performance is a noticeable divergence from the S&P 500’s 9% return.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 1.7%. This drop is a stark contrast from the S&P 500’s 9% gain.
Medical equipment and services company Steris (NYSESTE). fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 5.6% year on year to $1.37 billion. Its non-GAAP profit of $2.32 per share was in line with analysts’ consensus estimates.
DUBLIN, IRELAND, Feb. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSESTE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 third quarter ended December 31, 2024. Total revenue from continuing operations for the third quarter of fiscal 2025 increased 6% to $1.4 billion compared with $1.3 billion in the third quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the third quarter also increased 6%.
DUBLIN, IRELAND, Jan. 28, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSESTE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on March 21, 2025, to shareholders of record at the close of business on February 20, 2025.
DUBLIN, IRELAND , Jan. 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSESTE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 third quarter financial results at 9:00 a.m. ET on February 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
DUBLIN, IRELAND, Jan. 21, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSESTE) (“STERIS” or the “Company”) today announced that a jury trial that had been ongoing since December 4, 2024, against Isomedix Operations, Inc. (“Isomedix”), a subsidiary of the Company, ended in a mistrial on January 17, 2025.
DUBLIN, IRELAND, Nov. 06, 2024 (GLOBE NEWSWIRE) -- - STERIS plc (NYSESTE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 second quarter ended September 30, 2024. Total revenue from continuing operations for the second quarter of fiscal 2025 increased 7% to $1.3 billion compared with $1.2 billion in the second quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the second quarter increased 7%.
DUBLIN, IRELAND, Oct. 30, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSESTE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. The dividend is payable on December 19, 2024, to shareholders of record at the close of business on November 19, 2024.
DUBLIN, IRELAND, Oct. 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSESTE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 second quarter financial results at 9:00 a.m. ET on November 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
DUBLIN, IRELAND, Aug. 26, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSESTE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Wednesday, September 4, 2024. Dan Carestio, President and CEO of STERIS will present at 1:50 p.m. Eastern Time.
DUBLIN, IRELAND , Aug. 06, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSESTE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 first quarter ended June 30, 2024. Total revenue from continuing operations for the first quarter of fiscal 2025 increased 8% to $1.3 billion compared with $1.2 billion in the first quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the first quarter increased 6%.
DUBLIN, IRELAND, July 31, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSESTE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly interim dividend of $0.57 per share. This represents a $0.05 increase in the dividend and the Company’s 19th consecutive year of dividend growth. The dividend is payable on September 20, 2024, to shareholders of record at the close of business on September 5, 2024.
DUBLIN, IRELAND, July 23, 2024 (GLOBE NEWSWIRE) -- STERIS plc (NYSESTE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2025 first quarter financial results at 9:00 a.m. ET on August 7, 2024. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc.
